Studiedocumentatie
| Open studies |
| Trial | EFC22965 (ROCKforward) | ||||
| Middelen | belumosudil versus best available therapy (BAT) | ||||
| Lijn | Leeftijd | Fase | Location | Status | |
|---|---|---|---|---|---|
| 1e lijn | ≥ 18 jaar | Fase 3 | Amsterdam UMC | Open | |
| Open studies |
| Trial | EFC22965 (ROCKforward) | ||||
| Middelen | belumosudil versus best available therapy (BAT) | ||||
| Lijn | Leeftijd | Fase | Location | Status | |
|---|---|---|---|---|---|
| 1e lijn | ≥ 18 jaar | Fase 3 | Amsterdam UMC | Open | |